Evidence map›Paper›PMID 39632829›Full record

ArticleNature communications2024

CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma.

Chen-Hui Luo, Li-Hong Hu, Jie-Yang Liu, Li Xia, Li Zhou, Ren-Hong Sun, Chen-Cen Lin, Xing Qiu, Biao Jiang, Meng-Ying Yang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chen-Hui Luo *Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li-Hong Hu *Institute of Dermatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jie-Yang Liu *Institute of Dermatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Li Xia *Department of Core Facility of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-7236-0855
Li ZhouDepartment of Core Facility of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ren-Hong SunGluetacs Therapeutics (Shanghai) Co., Ltd., Shanghai, China.
Chen-Cen LinShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Xing QiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Biao JiangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Meng-Ying YangInstitute of Dermatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. ymy@shsmu.edu.cn.
Xue-Hong ZhangCenter of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. zhangxuehong1984@163.com.ORCID 0000-0001-8040-4141
Xiao-Bao YangGluetacs Therapeutics (Shanghai) Co., Ltd., Shanghai, China. yang.xiaobao@gluetacs.com.ORCID 0000-0001-5266-7673
Guo-Qiang ChenDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. chengq@shsmu.edu.cn.ORCID 0000-0003-4936-2363
Ying LuInstitute of Dermatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. stove@shsmu.edu.cn.ORCID 0000-0003-4657-0810

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82170179,81970131, 81770146, 82293661, 92253303, 32171431
6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-Hodgkin lymphoma originating in the skin and invading the systemic hematopoietic system. Current treatments, including chemotherapy and monoclonal antibodies yielded limited responses with high incidence of side effects, highlighting the need for targeted therapy. Screening with small inhibitors library, herein we identify cyclin dependent kinase 9 (CDK9) as a driver of CTCL growth. Single-cell RNA-seq analysis reveals a CDK9

Indexed as

Cyclin-Dependent Kinase 9Lymphoma, T-Cell, CutaneousRetinoic Acid Receptor alphaTretinoinTumor Suppressor ProteinsUbiquitin-Protein LigasesXenograft Model Antitumor AssaysAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceMice, Inbred NODProteolysisSkin NeoplasmsCDK9 protein, humanCyclin-Dependent Kinase 9HUWE1 protein, humanRARA protein, humanRetinoic Acid Receptor alphaTretinoinTumor Suppressor ProteinsUbiquitin-Protein Ligases

Identifiers

PMID39632829
PMCPMC11618697

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.